DIACEUTICS PLC

Environmental & Social Information • Sep 21, 2021

National Storage Mechanism | Additional information

RNS Number : 3750M

Diaceutics PLC

21 September 2021

21 September 2021

Diaceutics PLC

("Diaceutics" or "the Company")

Diaceutics nominated as finalists for Health Tech Awards 2021

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, is pleased to announce that the Company has been named as a finalist in four categories at the Health Tech Awards 2021 organised by the UK's Health Tech Newspaper, which seeks to celebrate the technology helping to shape the healthcare industry. The categories include Best Use of Data, Best Use of AI & Automation, Innovation in Digital Pathways and Excellence in Cloud Technologies.

The HTN Awards help to share and celebrate digital teams, programmes, innovations, and health tech suppliers that have made a difference throughout the year.

Diaceutics' entries focus on the application of machine learning and AI to identify the best possible testing journey for patients using DDPs® (Diagnostic Deductive Pathways). Each DDP developed by the company represents a series of algorithms used to describe specific disease biomarker datapoints to track trends at disease level insights via its DXRX platform.

The Company's DXRX platform is the world's first diagnostic commercialisation platform for Precision Medicine.  The DXRX platform integrates multiple pipelines of real-world diagnostic testing data from a global network of laboratories, alongside diagnostic profiling meta data and CMS and commercial claims data, resulting in a data repository of more than 409 million de-identified patient records across 53 countries.

Through machine learning and the standardisation of these millions of aggregated de-identified patient testing events, Diaceutics has identified the best possible DDP® for patients at disease level for 49 diseases to date, providing the industry with a guide to 'getting the right medicines to the right patients, faster'.

With 476 potential Precision Medicine therapies now in late phase of development and over 30 per cent of all FDA approvals between 2018-2020 being for Precision Medicines, the pipeline of therapies requiring a companion diagnostic solution is rapidly growing.

Peter Keeling, Chief Executive Officer, Diaceutics commented: "We are delighted to be nominated as finalists for these four awards. The growing industry recognition we are receiving serves as a testament to our team and the value we are able to deliver to the world's leading pharmaceutical companies. We are committed to leveraging deep disease level data analytics and implementation solutions to improve the diagnostic infrastructure for these companies and more importantly, to ensure that every patient gets access to the right treatment at the right time."  

Enquiries:

Diaceutics PLC
Philip White, Chief Financial Officer	Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker)	Tel: +44 (0)20 7710 7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR	Tel: +44(0)20 3405 0205
Caroline Forde	diaceutics@almapr.co.uk
Robyn Fisher
Kieran Breheny Matthew Young

About Diaceutics

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®. 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAFLFERARIIFIL